Anti-Tyrosine Phosphatase (IA-2A) IgG ELISA Kit

Short Description:

The antigen for anti-tyrosine phosphatase antibodies is a fragment of pancreatic islet cell 512, primarily present in pancreatic beta cells. Also known as protein tyrosine phosphatases, these antibodies are key participants in protein tyrosine phosphorylation. It is generally accepted that tyrosine phosphatase antibodies are mainly produced in patients with type 1 diabetes. Approximately 65% of newly diagnosed type 1 diabetes patients test positive for tyrosine phosphatase antibodies, which are considered specific to type 1 diabetes. They appear after glutamic acid decarboxylase antibodies. The detection rate is higher in children, with a sensitivity of 50-60%, specificity of 98-99%, and predictive value of 30-50%. When islet cell antibodies, glutamic acid decarboxylase antibodies, and tyrosine phosphatase antibodies are detected, 98% of pre-diabetic or newly diagnosed patients express at least one antibody, 80% express two, and 25% express all three. Since positive results for each antibody are often inconsistent, testing for any single islet cell antibody may lead to missed diagnoses. Combined detection of multiple antibodies can improve the detection rate for type 1 diabetes. Type 1 diabetes requires treatment with insulin injections and is currently incurable. However, through scientific and rational management, patients’ quality of life can be improved and their lifespan extended. Targeted health education helps patients adjust their mindset, maintain a healthy lifestyle, pay attention to disease monitoring, and adhere to a healthy diet and moderate exercise to support treatment—all aimed at preventing and reducing the occurrence of complications.